vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.
New Fortress Energy Inc. is the larger business by last-quarter revenue ($326.2M vs $281.3M, roughly 1.2× Guardant Health, Inc.). Guardant Health, Inc. runs the higher net margin — -45.7% vs -259.7%, a 214.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -7.0%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-134.8M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -26.8%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
GH vs NFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $326.2M |
| Net Profit | $-128.5M | $-847.1M |
| Gross Margin | 64.6% | 35.5% |
| Operating Margin | -43.0% | -193.0% |
| Net Margin | -45.7% | -259.7% |
| Revenue YoY | 39.4% | -7.0% |
| Net Profit YoY | -15.8% | -277.4% |
| EPS (diluted) | $-1.01 | $-3.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $326.2M | ||
| Q3 25 | $265.2M | $240.3M | ||
| Q2 25 | $232.1M | $228.1M | ||
| Q1 25 | $203.5M | $384.9M | ||
| Q4 24 | $201.8M | $350.7M | ||
| Q3 24 | $191.5M | $446.0M | ||
| Q2 24 | $177.2M | $291.2M | ||
| Q1 24 | $168.5M | $609.5M |
| Q4 25 | $-128.5M | $-847.1M | ||
| Q3 25 | $-92.7M | $-263.0M | ||
| Q2 25 | $-99.9M | $-546.5M | ||
| Q1 25 | $-95.2M | $-175.4M | ||
| Q4 24 | $-111.0M | $-224.4M | ||
| Q3 24 | $-107.8M | $9.3M | ||
| Q2 24 | $-102.6M | $-88.9M | ||
| Q1 24 | $-115.0M | $54.1M |
| Q4 25 | 64.6% | 35.5% | ||
| Q3 25 | 64.7% | 18.1% | ||
| Q2 25 | 65.0% | 8.4% | ||
| Q1 25 | 63.3% | 21.4% | ||
| Q4 24 | 61.6% | 17.6% | ||
| Q3 24 | 61.1% | 27.1% | ||
| Q2 24 | 59.1% | 23.8% | ||
| Q1 24 | 61.2% | 62.4% |
| Q4 25 | -43.0% | -193.0% | ||
| Q3 25 | -37.3% | -37.4% | ||
| Q2 25 | -45.9% | -170.3% | ||
| Q1 25 | -54.6% | -3.3% | ||
| Q4 24 | -62.4% | 65.0% | ||
| Q3 24 | -61.3% | 17.8% | ||
| Q2 24 | -56.8% | 12.3% | ||
| Q1 24 | -59.2% | 30.4% |
| Q4 25 | -45.7% | -259.7% | ||
| Q3 25 | -35.0% | -109.4% | ||
| Q2 25 | -43.0% | -239.6% | ||
| Q1 25 | -46.8% | -45.6% | ||
| Q4 24 | -55.0% | -64.0% | ||
| Q3 24 | -56.3% | 2.1% | ||
| Q2 24 | -57.9% | -30.5% | ||
| Q1 24 | -68.2% | 8.9% |
| Q4 25 | $-1.01 | $-3.03 | ||
| Q3 25 | $-0.74 | $-0.96 | ||
| Q2 25 | $-0.80 | $-1.99 | ||
| Q1 25 | $-0.77 | $-0.65 | ||
| Q4 24 | $-0.90 | $-1.10 | ||
| Q3 24 | $-0.88 | $0.03 | ||
| Q2 24 | $-0.84 | $-0.42 | ||
| Q1 24 | $-0.94 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $226.5M |
| Total DebtLower is stronger | $1.5B | $8.2B |
| Stockholders' EquityBook value | $-99.3M | $182.6M |
| Total Assets | $2.0B | $10.6B |
| Debt / EquityLower = less leverage | — | 44.78× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $226.5M | ||
| Q3 25 | $580.0M | $145.2M | ||
| Q2 25 | $629.1M | $551.1M | ||
| Q1 25 | $698.6M | $447.9M | ||
| Q4 24 | $525.5M | $492.9M | ||
| Q3 24 | $585.0M | $90.8M | ||
| Q2 24 | $933.7M | $133.0M | ||
| Q1 24 | $1.0B | $143.5M |
| Q4 25 | $1.5B | $8.2B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $8.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $182.6M | ||
| Q3 25 | $-354.5M | $1.1B | ||
| Q2 25 | $-305.5M | $1.3B | ||
| Q1 25 | $-250.8M | $1.8B | ||
| Q4 24 | $-139.6M | $1.9B | ||
| Q3 24 | $-60.1M | $1.6B | ||
| Q2 24 | $-1.6M | $1.6B | ||
| Q1 24 | $68.3M | $1.7B |
| Q4 25 | $2.0B | $10.6B | ||
| Q3 25 | $1.3B | $12.0B | ||
| Q2 25 | $1.3B | $12.0B | ||
| Q1 25 | $1.3B | $13.1B | ||
| Q4 24 | $1.5B | $12.9B | ||
| Q3 24 | $1.5B | $12.0B | ||
| Q2 24 | $1.6B | $11.4B | ||
| Q1 24 | $1.7B | $10.9B |
| Q4 25 | — | 44.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-76.2M |
| Free Cash FlowOCF − Capex | $-54.2M | $-134.8M |
| FCF MarginFCF / Revenue | -19.3% | -41.3% |
| Capex IntensityCapex / Revenue | 9.9% | 18.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-76.2M | ||
| Q3 25 | $-35.4M | $-171.0M | ||
| Q2 25 | $-60.3M | $-329.0M | ||
| Q1 25 | $-62.7M | $-7.2M | ||
| Q4 24 | $-64.5M | $445.3M | ||
| Q3 24 | $-51.1M | $-20.0M | ||
| Q2 24 | $-94.0M | $113.9M | ||
| Q1 24 | $-30.3M | $63.0M |
| Q4 25 | $-54.2M | $-134.8M | ||
| Q3 25 | $-45.8M | $-231.6M | ||
| Q2 25 | $-65.9M | $-726.7M | ||
| Q1 25 | $-67.1M | $-262.3M | ||
| Q4 24 | $-83.4M | $-210.3M | ||
| Q3 24 | $-55.3M | $-367.0M | ||
| Q2 24 | $-99.1M | $-493.2M | ||
| Q1 24 | $-37.2M | $-457.9M |
| Q4 25 | -19.3% | -41.3% | ||
| Q3 25 | -17.3% | -96.4% | ||
| Q2 25 | -28.4% | -318.6% | ||
| Q1 25 | -33.0% | -68.2% | ||
| Q4 24 | -41.3% | -60.0% | ||
| Q3 24 | -28.9% | -82.3% | ||
| Q2 24 | -55.9% | -169.3% | ||
| Q1 24 | -22.1% | -75.1% |
| Q4 25 | 9.9% | 18.0% | ||
| Q3 25 | 3.9% | 25.2% | ||
| Q2 25 | 2.4% | 174.4% | ||
| Q1 25 | 2.2% | 66.3% | ||
| Q4 24 | 9.4% | 187.0% | ||
| Q3 24 | 2.2% | 77.8% | ||
| Q2 24 | 2.9% | 208.4% | ||
| Q1 24 | 4.1% | 85.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -2.15× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
NFE
Segment breakdown not available.
